CAD and Encephalopathy: In fact, the current protocol should be regularly updated in order to accommodate newly discovery IEMs, such as uridine-responsive encephalopathy due to biallelic CAD mutations and vitamin B6-responsive epileptic encephalopathy due to biallelic PLPBP mutations (38, 39).